Ranibizumab 2.3mg/0.23ml solution for injection vials
Requires a prescription from a doctor or prescriber
Miscellaneous ophthalmic preparations
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ranibizumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ranibizumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
6 branded products available
MHRA licensed products
View all licensed products for Ranibizumab on the MHRA register
Byooviz 2.3mg/0.23ml solution for injection vials
Lucentis 2.3mg/0.23ml solution for injection vials
Ongavia 2.3mg/0.23ml solution for injection vials
Rimmyrah 2.3mg/0.23ml solution for injection vials
Ximluci 2.3mg/0.23ml solution for injection vials
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Ranibizumab
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(14)
Ranibizumab for treating diabetic macular oedema (TA274)
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)
Age-related macular degeneration (NG82)
Aflibercept for treating choroidal neovascularisation (TA486)
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)
Faricimab for treating wet age-related macular degeneration (TA800)
Faricimab for treating diabetic macular oedema (TA799)
Brolucizumab for treating diabetic macular oedema (TA820)
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Brolucizumab for treating wet age-related macular degeneration (TA672)
Aflibercept for treating diabetic macular oedema (TA346)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
The pathogenesis of neovascular eye diseases is not fully understood; however, v…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.5 mg
[A2298]…
Half-life
25 weeks
[L38978]…
Protein binding
Volume of distribution
2.77 L
[A246404]…
Metabolism
[L38983]…
Elimination
Clearance
24.8 L
[A246404]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.[L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625][L43513][L49141]
[L38978][L41434]
Ranibizumab injection for intravitreal use via ocular implant is used to treat Neovascular (wet) Age-related Macular Degeneration (AMD) in patients who have responded to at least two intravitreal injections of a VEGF inhibitor.
[L38983]
In Canada, ranibizumab is approved to treat adult patients with neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema, macular edema secondary to retinal vein occlusion, choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), and choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, postinflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy.
[L49136]
In Europe, ranibizumab is also approved for the treatment of similar ophthalmological conditions, including neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), and visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) or choroidal neovascularisation (CNV) for adults and retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease for preterm infants.
[L41434]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 388 interactions
[L38978]
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody directed against human VEGF-A.[A11475] Ranibizumab binds to VEGF-A with high affinity as well as its biologically active forms, such as VEGF165, VEGF121, and VEGF110.[A246394] Notably, VEGF165 is the most predominant isoform in the human eye that promotes ocular neovascularization. VEGF165 enhances vascular permeability, inhibits apoptosis, and causes endothelial-cell mobilization from the bone marrow and differentiation for angiogenesis.[A2301] Ranibizumab binds to the receptor-binding site of VEGF-A, preventing it from binding to its receptors - VEGFR1 and VEGFR2 - that are expressed on the surface of endothelial cells. Ranibizumab thereby attenuates endothelial cell proliferation, vascular leakage, and new blood vessel formation.[L38978]
As ranibizumab has one binding site for VEGF, two drug molecules bind to one VEGF dimer.[A246399] Ranibizumab lacks the Fc region of an antibody, which may prevent the drug from causing intraocular inflammation following intravitreal injection.[A11475]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A2298]
Following monthly intravitreal administration of 0.5 mg ranibizumab in patients with neovascular (wet) age-related macular degeneration, the mean Cmax (±SD) was 1.7 (± 1.1) ng/mL.
[L38978]
Following an implant insertion, the mean (±SD) Cmax of ranibizumab was 0.48 (±0.17) ng/mL and median Tmax was 26 days, with a range of one to 89 days.
[L38983]
[L38978]
The half-life of ranibizumab implant is approximately 25 weeks.
[L38983]
[A246404]
Ranibizumab is not shown to accumulate in serum.
[L38983]
Due to its small size from lacking the Fc region of an antibody, ranibizumab achieves enhanced diffusion into the retina and choroid.
[A246399][A11475]
[L38983]
[A246404]
Proteins and enzymes this drug interacts with in the body
PMID:35455969
Involved in protecting cells from hypoxia-mediated cell death (By similarity)
ATC S01LA04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ranibizumab
Additional database identifiers
Drugs Product Database (DPD)
20146
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12680
GenAtlas
VEGF
GeneCards
VEGFA
GenBank Gene Database
M32977
GenBank Protein Database
181971
UniProt Accession
VEGFA_HUMAN
International reference pricing
Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.
Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.
Patent information
All patents expired, 1 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: